Arcus Biosciences Inc. (RCUS), a clinical-stage, global biopharmaceutical company designing combination therapies for cancer, expects to have six ongoing phase III trials for three distinct programs by the beginning of next year.
The investigational drugs in the pipeline include Domvanalimab, Zimberelimab, Casdatifan, Quemliclustat, Etrumadenant, AB598 and AB801.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com